Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD

BACKGROUND: Formoterol fumarate inhalation solution (FFIS; Perforomist(®)) is a long-acting β(2)-agonist (LABA) marketed in the US as a nebulized COPD maintenance treatment. Because long-term LABA use was associated with a potential increased risk of exacerbation or death in asthma patients, the US...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanania, Nicola A, Sethi, Sanjay, Koltun, Arkady, Ward, Jonathan K, Spanton, Jacqui, Ng, Dik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311322/
https://www.ncbi.nlm.nih.gov/pubmed/30643398
http://dx.doi.org/10.2147/COPD.S173595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311322/
https://www.ncbi.nlm.nih.gov/pubmed/30643398
http://dx.doi.org/10.2147/COPD.S173595

Ejemplares similares